Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SN301A in GPC3-Positive Advanced Hepatocellular Carcinoma
NCT06652243Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SENTI-301 in hepatocellular carcinoma (HCC), sponsored by Shanghai General Hospital. Primary endpoints: Dose-limiting toxicities at 28 days and Incidence and severity of adverse events and serious adverse events at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
SENTI-301
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06652243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652243.